profit from every $100 of sales.
$0$100
Niagen Bioscience
$2.10-2.56% today
-70.7% in 1 year
1-year low $2.071-year high $7.18
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $9.55 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Niagen Bioscience sold, what it kept, and what it did with the cash.
Sales went from $72.1 million in 2022 to $129 million in 2025, with $17.4 million of profit last year.
SalesProfit
Niagen Bioscience handed back 2% of the cash it generated last year.
Buybacks $251,000
Free cash flow 2025$13M
Bought back its own shares$251,000
Paid as dividends–
Cash vs. debt$65M vs. $3M
Niagen Bioscience vs. similar companies
Niagen Bioscience grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Niagen Bioscience | 9.5× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Niagen Bioscience's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 72 | 84 | 100 | 129 | |
| 43 | 51 | 62 | 83 | |
| -19 | -6 | 8 | 14 | |
| -17 | -4 | 9 | 16 | |
| -17 | -5 | 9 | 17 | |
| -0.24 | -0.07 | 0.11 | 0.20 | |
| 59.4% | 60.8% | 61.8% | 64.3% | |
| -25.9% | -6.7% | 7.8% | 11.0% | |
| -23.0% | -5.9% | 8.6% | 13.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 54 | 55 | 68 | 106 |
| Cash | 20 | 27 | 45 | 65 |
| Total debt | 4 | 3 | 3 | 3 |
| Total liabilities | 25 | 27 | 22 | 30 |
| 29 | 28 | 46 | 77 | |
| 70 | 75 | 78 | 85 | |
| -44.7% | -13.9% | 12.5% | 14.2% | |
| -57.7% | -17.4% | 18.5% | 22.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | 7 | 12 | 14 | |
| 0 | 0 | 0 | 0 | |
| -15 | 7 | 12 | 13 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 6 | 5 | 4 | 6 |
Valuation
- 9.5×
- 8.2×
- –
- 3.9×
- 1.3×
- 12.6×
- 6.6×
- 8.0%
- 10.5%
- 0.0%
Profitability
- 64.3%
- 11.0%
- 13.4%
- 10.3%
- 11.4%
- -20.2%
- 25.4%
- 16.3%
- 12.1%
- 5.0%
Growth
- +21.6%
- –
- +10.0%
- –
- +4.2%
Financial health
- -4.8×
- 0.03
- 2.3%
- –
- 4.61
- 3.55
- 1.14
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 23%of 958
Top 45%of 888
Top 9%of 600
Top 26%of 889
Top 11%of 987
What analysts expect
- Average price target
- $14.00
- Range
- $14.00 – $14.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.07 | 0.06 | +16.7% |
| Mar 4, 2026 | 0.03 | 0.02 | +50.0% |
| Nov 4, 2025 | 0.05 | 0.02 | +233.3% |
| Aug 6, 2025 | 0.04 | 0.02 | +100.0% |
| May 7, 2025 | 0.04 | 0.02 | +100.0% |
| Mar 4, 2025 | 0.03 | 0.02 | +50.0% |
| Oct 31, 2024 | 0.02 | 0.01 | +100.0% |
| Jun 30, 2024 | -0.00 | -0.02 | +99.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
58No pass
Benjamin Graham
58No pass
Philip Fisher
62Pass
Peter Lynch
86Pass
Joel Greenblatt
56No pass
Charlie Munger
48No pass
Terry Smith
45No pass
Questions about Niagen Bioscience
Is Niagen Bioscience a good stock to buy?
A solid business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Niagen Bioscience AI analysis
What does Niagen Bioscience do?
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide. It is in Biotechnology.
Does Niagen Bioscience pay a dividend?
No. Niagen Bioscience does not pay a dividend at the moment; in 2025 it returned $251,000 to shareholders by buying back its own shares.
Is Niagen Bioscience stock halal?
No. Niagen Bioscience does not pass our halal screen: its cash and confirmed interest-bearing investments are 39% of its market value, at or above the 33% limit. How we check
How has Niagen Bioscience stock done over the past year?
Down 70.7% over the past twelve months, to $2.10. It traded between $2.07 and $7.18 and is 70.8% below its high.
Who are Niagen Bioscience's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Niagen Bioscience's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.